Psilera

Psilera, a Tampa-based biotech company, has taken a significant step in advancing treatments for dementia with its psilocybin-based drug, PSIL-006. Unlike traditional psychedelics, this pharmaceutical version of psilocybin is designed to avoid inducing the hallucinogenic effects commonly associated...

Biopharma company Psilera Inc. announced it has selected its first clinical candidate, a novel drug sharing several of psilocybin’s properties but without the hallucinogenic effects. Psilera’s work involves rethinking natural psychoactive substances into “effective and...

Next-gen therapeutics developer Psilera Inc. has achieved a preclinical milestone by having all its first cohort of drug candidates, designed and synthesized in-house, show no hallucinogenic effects in animals. The group includes six patent-pending compounds with novel structural features...

Psychedelics VC fund Iter Investments has recently closed its last round of Fund I with over $20 million committed, a successful outcome considering the targeted raise in their first fund launch in April 2021, and an indication of investor interest in the psychedelics market. Iter’s team...

Contents California Psychedelics Bill Put On Hold Until 2022  FSD Pharma To Purchase Lucid Psycheceuticals For $9 Million Psycheceutical Licenses New Delivery Technologies For Psychedelics Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression Awakn To...

Psilera, a Florida-based biotechnology company, has initiated preclinical studies with new psychedelic derivatives aimed at reducing alcohol consumption. The Study Psilera Inc., working in collaboration with University of South Florida (USF) researchers will conduct the first in vivo screening...

Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS.”  The company had an...

Florida-based Psilera Inc. has secured $2.5 million in funding for research, scientific and clinical personnel hiring and general working purposes. The company issued approximately 4.3 million shares to private buyers at a cost of $0.57 per share. Psilera has developed a patent-pending DMT...